|
ALBUQUERQUE, N.M., June 16, 2009
(GLOBE NEWSWIRE) -- The New Mexico Institute of Mining
and Technology (NM Tech) will present data from Biomoda,
Inc. (OTCBB:BMOD
- News)
on its non-invasive, inexpensive and accurate diagnostic
test for the early detection of lung cancer at the 13th
World Conference on Lung Cancer in San Francisco, CA,
July 31 to August 4, 2009.
NM Tech and two affiliated entities,
the Institute for Complex Additive Systems Analysis (ICASA)
and the Computational Analysis and Network Enterprise
Solutions, LLC (CAaNES), are working with
Albuquerque-based medical diagnostics company Biomoda,
Inc. on the patented assay for early detection of
cancer.
Dr. Srinivas Mukkamala, a senior
research scientist with ICASA, will present an abstract
titled "Non-Intrusive and Extremely Early Detection
of Lung Cancer Using TCPP (Biomoda Lab Cultured Lung
Cancer Data)," in poster format to the 7,000 lung
cancer professionals expected to attend the conference.
TCPP, or meso-tetra (4 carboxyphenyl) porphine, is the
chemical compound underlying Biomoda's patented
diagnostic assay.
Currently in Phase II clinical trials,
Biomoda's diagnostic is a porphyrin application that
preferentially binds to cancerous or aberrant cells
extracted from deep lung sputum samples. Cancerous cells
treated with Biomoda's patented CyPath(tm) labeling
solution fluoresce red under ultraviolet light.
Mukkamala's presentation at the World
Conference on Lung Cancer will focus on the computer
modeling and data analysis work ICASA and CAaNES have
done with Biomoda's images and data. "Our work will
allow Biomoda to automate the screening process, which
is a critical step toward making the diagnostic
available to large populations," Mukkamala said.
"The computer modeling will also enhance the
accuracy of the assay."
"The opportunity to present the
Biomoda technology to the top clinicians and scientists
in our field is a big step forward for us," said
John Cousins, Biomoda President and CEO. "Since
only 16 percent of lung cancers today are diagnosed
early enough to be cured, this audience will understand
the tremendous life-saving potential of an easy,
non-invasive, inexpensive and, above all, accurate
screening tool for lung cancer."
Sponsored by the International
Association for the Study of Lung Cancer (IASLC), the
World Conference on Lung Cancer is one of the largest
international gatherings of professionals in the field,
focusing on both research science and advances in the
treatment of lung cancer, the leading cause of cancer
deaths worldwide.
Follow news about Biomoda on Facebook
and Twitter.
|
